NIH plan to diversify cancer clinical trials ends in costly failure

Paying travel costs for prospective study participants didn't increase trial diversity — but it drove up costs for the National Cancer Institute. 

June 14, 2024 Check out STAT+

Sponsored By

Adobe NIH wanted to make cancer research more diverse. The effort turned out to be a costly failure Cancer researchers tested out paying for more travel costs for patients, but the effort didn't result in more diverse trials. By John Wilkerson STAT+ | New AI for biopsies can analyze microscopy images, talk to pathologists about your tumor PathChat is a new AI model for pathology, published Wednesday in Nature by Harvard researcher Faisal Mahmood and his collaborators. By Brittany Trang STAT+ | Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried A wonky policy shift in the arcane world of "health technology assessments" has drugmakers big and small racing to adapt. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser